Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 48.86

-1.7%

Feb 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2064)	11/20/2000 4:27:39 PM
From: nigel bates	Read Replies (3) of 52153

"...and therefore traditional accounting systems are at loss to capture much of what goes on... So why try ? There's no accounting event because no money changes hands." Good. The 'value' created when a drug passes a clinical trial is still provisional, unless there's a milestone payment involved, ditto software going beta. If it's anyone's role to value this, it's the market's (or a bunch of analysts', LOL), and we've seen how wildly erratic such attempts are. Accountants should stick to doing what they do best, & leave the (over)imaginative stuff to others. By all means report R&D expenditure as a separate item, but remember that it's still expenditure. nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next